<code id='5F57183FDE'></code><style id='5F57183FDE'></style>
    • <acronym id='5F57183FDE'></acronym>
      <center id='5F57183FDE'><center id='5F57183FDE'><tfoot id='5F57183FDE'></tfoot></center><abbr id='5F57183FDE'><dir id='5F57183FDE'><tfoot id='5F57183FDE'></tfoot><noframes id='5F57183FDE'>

    • <optgroup id='5F57183FDE'><strike id='5F57183FDE'><sup id='5F57183FDE'></sup></strike><code id='5F57183FDE'></code></optgroup>
        1. <b id='5F57183FDE'><label id='5F57183FDE'><select id='5F57183FDE'><dt id='5F57183FDE'><span id='5F57183FDE'></span></dt></select></label></b><u id='5F57183FDE'></u>
          <i id='5F57183FDE'><strike id='5F57183FDE'><tt id='5F57183FDE'><pre id='5F57183FDE'></pre></tt></strike></i>

          leisure time

          leisure time

          author:knowledge    Page View:8742

          When is negative data positive enough? Who gets credit for scientific breakthroughs? And wasn’t biotech supposed to bounce back?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain the story of Svetlana Mojsov, a chemist who played a vital role in the discovery of GLP-1 who has spent decades fighting for proper recognition. We also discuss the latest news in the life sciences, including the FDA hearing on a BrainStorm Cell Therapeutics’ polarizing ALS treatment, the end of the road for a once-vaunted drug developer, and the sorry state of biotech stocks.

          advertisement

          For more on what we cover, here’s the Mojsov story; here’s the latest on BrainStorm; here’s the news on Intercept Pharmaceuticals; here’s more on the biotech market; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          focus

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          As biotech industry slumps, bioscience job market is upside down
          As biotech industry slumps, bioscience job market is upside down

          ChristineKao/STATAfterearningherdoctorateincellbiologyattheUniversityofPennsylvaniainJune,SierraColl

          read more
          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more

          As biotech industry slumps, bioscience job market is upside down

          ChristineKao/STATAfterearningherdoctorateincellbiologyattheUniversityofPennsylvaniainJune,SierraColl